Tin tức & Cập nhật

Which AECOPD patients are likely to test positive for flu?
Which AECOPD patients are likely to test positive for flu?
25 Jan 2022 bởiTristan Manalac

In patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD), higher body temperature and heart rate, along with low white cell counts, are strong predictors of testing positive for influenza, according to a recent Singapore study.

Which AECOPD patients are likely to test positive for flu?
25 Jan 2022
Very low-calorie ketogenic diet plus omega-3 promotes weight loss in class I obesity
Very low-calorie ketogenic diet plus omega-3 promotes weight loss in class I obesity
25 Jan 2022

For individuals with class I obesity, a very low-calorie ketogenic diet (VLCKD) with omega-3 supplementation results in fat mass reduction while preserving fat-free mass (FFM), as shown in a study. Furthermore, there are improvements seen in satiety hormones, such as higher ghrelin and lower leptin, and in the metabolic profiles.

Very low-calorie ketogenic diet plus omega-3 promotes weight loss in class I obesity
25 Jan 2022
Risk stratification criteria show good prognostic value in CRPC, but not enough to guide treatment
Risk stratification criteria show good prognostic value in CRPC, but not enough to guide treatment
24 Jan 2022
Esaxerenone produces favourable night-time BP-lowering effect in Asians
Esaxerenone produces favourable night-time BP-lowering effect in Asians
24 Jan 2022 bởiJairia Dela Cruz

The novel highly selective mineralocorticoid receptor blocker esaxerenone holds promise in the treatment of nocturnal hypertension, yielding substantial reductions in night-time blood pressure (BP), especially in Japanese patients with a riser pattern, as well as in N-terminal pro B-type natriuretic peptide (NT-proBNP) levels, according to a post hoc analysis of a phase III study.

Esaxerenone produces favourable night-time BP-lowering effect in Asians
24 Jan 2022
KEEPsAKE findings boost risankizumab efficacy, safety for PsA
KEEPsAKE findings boost risankizumab efficacy, safety for PsA
24 Jan 2022 bởiAudrey Abella

In individuals with psoriatic arthritis (PsA) who have inadequate response or intolerance to ≥1 csDMARD*, the monoclonal antibody risankizumab significantly improved manifestations of PsA, according to the 24-week findings of the phase III KEEPsAKE 1 trial.

KEEPsAKE findings boost risankizumab efficacy, safety for PsA
24 Jan 2022